June 29, 2023 News by Margarida Maia, PhD Ocrevus keeps MS activity stable after stopping Tysabri: Study Switching from Tysabri (natalizumab) to Ocrevus (ocrelizumab) does not appear to increase disease activity in people with relapsing forms of multiple sclerosis (MS) and stable disease, with most patients continuing to show no relapses or brain imaging findings one year after the transition, a clinical study shows.
June 28, 2023 News by Margarida Maia, PhD Early use of high-efficacy DMTs may keep patients on therapy longer Starting treatment with a high-efficacy disease-modifying therapy (DMT), rather than one with lesser efficacy, may reduce the number of times people with multiple sclerosis (MS) switch therapies due to a lack of effectiveness, a study of survey responses from doctors suggests. High-efficacy DMTs often are perceived to have…
June 26, 2023 News by Margarida Maia, PhD Education found to help with MS treatment adherence in Iran An educational intervention program was found to help improve treatment adherence among people with multiple sclerosis (MS) receiving injectable therapies in a clinical trial in Iran. The program was designed based on the theory of planned behavior — a psychological premise that assumes people act rationally according to their…
June 22, 2023 News by Margarida Maia, PhD For women with MS, finding coping strategies for sex is more satisfying The sexual satisfaction of women with multiple sclerosis (MS) improved when they actively sought out ways to deal with the practical challenges related to sexuality instead of just relying on managing their emotions, a study finds. It’s therefore important for women with MS to consider a problem-focused coping strategy…
June 12, 2023 News by Margarida Maia, PhD FDA clears way for Phase 1 study of PIPE-791 in healthy volunteers Pipeline Therapeutics will soon launch a Phase 1 clinical study to test PIPE-791, one of its candidate treatments for multiple sclerosis (MS), in healthy volunteers. The announcement follows a go-ahead from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND) application to initiate clinical…
June 1, 2023 News by Margarida Maia, PhD Stress in MS linked to worse disability, more burden in US survey Being exposed to stress as children or adults makes it more likely that people with multiple sclerosis (MS) will experience more disability and/or a heavier burden from relapses, according to a new survey study of more than 700 people in the U.S. “MS is the leading cause of non-traumatic…
May 26, 2023 News by Margarida Maia, PhD Fertility rates about 2 times lower in women with MS: Study in Italy While fertility rates in women with multiple sclerosis (MS) have been increasing over time, they remain about two times lower than in the general population, a study in Italy has found. “There is a large gap in fertility between women with MS and the general population that needs to…
May 15, 2023 News by Margarida Maia, PhD 1st group of healthy volunteers dosed in Phase 1 trial of ‘Lucid-MS’ FSD Pharma has completed dosing in the first group of healthy volunteers enrolled in its Phase 1 clinical trial testing Lucid-21-302, an oral medication candidate for all types of multiple sclerosis (MS). The medication, also known as Lucid-MS, was first given to a sentinel subject — one…
May 8, 2023 News by Margarida Maia, PhD Myeloid cells with added ‘backpack’ may help halt MS inflammation Attaching a kind of molecule backpack to myeloid cells — a type of immune cells involved in the inflammatory attack that drives multiple sclerosis (MS) — may help to halt inflammation and damage in the brain in MS by modulating immune cell activity, a study…
April 24, 2023 News by Margarida Maia, PhD Region in Japan sees steady increase in MS prevalence over 20 years Tokachi, a region in northern Japan, has seen a steady increase in the prevalence or proportion of people in the population living with multiple sclerosis (MS) over the past two decades, a recent study found. Data show the disease has also become more common in women in northern…
April 20, 2023 News by Margarida Maia, PhD First participant completes dosing in Phase 1 Lucid-MS trial The first participant has completed dosing in a Phase 1 clinical trial testing FSD Pharma‘s Lucid-21-302, an experimental oral medication for all types of multiple sclerosis (MS), in healthy volunteers. After receiving a green light from Health Canada to launch the first-in-human trial, the company began by…
April 18, 2023 News by Margarida Maia, PhD Vitamin D at high dose doesn’t lower MS relapse risk, Phase 3 trial finds A high-dose vitamin D supplement did not reduce the risk of relapses in people with relapsing-remitting multiple sclerosis (RRMS) already using a disease-modifying therapy to control disease activity, according to findings of a Phase 3 clinical trial. The VIDAMS study (NCT01490502) — standing for Vitamin D…
April 11, 2023 News by Margarida Maia, PhD Lemtrada aids cognitive skills, eases depression in real-world MS study One year of treatment with Lemtrada (alemtuzumab) significantly improved cognitive abilities, particularly with processing speed, and eased depression in people with relapsing forms of multiple sclerosis (MS), a small real-world study reported. Most of the 39 patients (92%) evaluated after that treatment year showed either stable or improved…
April 6, 2023 News by Margarida Maia, PhD Women with MS at higher risk of having premature, smaller babies Women with multiple sclerosis (MS) may have a higher risk of giving birth to premature or smaller babies, but it’s unclear if using MS medications during pregnancy has an effect on the baby’s health, according to a systematic review. The long-term health outcomes of children whose mothers have…
April 4, 2023 News by Margarida Maia, PhD CHMP favors Briumvi for approval to treat relapsing forms of MS in EU An arm of the European Medicines Agency favors the approval of Briumvi (ublituximab) to treat adults with active, relapsing forms of multiple sclerosis (MS) across the European Union (EU). The Committee for Medicinal Products for Human Use (CHMP) opinion is based on data from twin Phase 3 trials,…
April 4, 2023 News by Margarida Maia, PhD Sensoready Pen easier to use for MS therapy than other devices: Survey Both people with multiple sclerosis (MS) and their nurses prefer the Sensoready Pen for administering Kesimpta (ofatumumab) — an approved MS treatment that’s injected subcutaneously, or under the skin — mostly because it’s easier to use than other available devices, a survey study found. With this pen “patients…
March 30, 2023 News by Margarida Maia, PhD Tiziana to launch clinical trial for MS therapy foralumab in late 2023 Tiziana Life Sciences plans to launch a Phase 2 clinical trial to investigate its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) in late 2023, the company announced. The decision follows a Type C meeting with the U.S. Food and Drug Administration (FDA), wherein…
March 21, 2023 News by Margarida Maia, PhD Early MS MRI markers linked to worse disability in 10 years time MRI scans of the brain acquired early on after the onset of multiple sclerosis (MS) may help predict disease severity and disability accumulation after 10 years, a new study found. In particular, there were two MRI biomarkers — inter-caudate diameter (ICD) and third ventricular width (TVW) — detected…
March 21, 2023 News by Margarida Maia, PhD Adult diagnostic criteria lacking at predicting future MS in children Predicting whether an asymptomatic child or adolescent with signs of demyelination on imaging scans will develop multiple sclerosis (MS) is difficult using adult diagnostic criteria, a small study found. The findings highlight the need for more suitable criteria for pediatric patients, which could let them begin treatment…
March 20, 2023 News by Margarida Maia, PhD No rise in MS patients’ risk of relapse seen with fertility treatments Disease relapses are no more likely in women with multiple sclerosis (MS) after fertility treatment than they were before such treatment, a study found. Researchers also observed that almost half of the women receiving fertility treatment were on disease-modifying MS therapies, which may have helped to keep a…
March 14, 2023 News by Margarida Maia, PhD Higher blood levels of Ocrevus lower confirmed disability progression risk Higher blood levels of Ocrevus (ocrelizumab) is associated with a significantly lower risk of confirmed disability progression during treatment in people with relapsing and progressive forms of multiple sclerosis (MS), according to an analysis of data from three Phase 3 clinical trials. Notably, the lower disability progression rates reported in…
February 21, 2023 News by Margarida Maia, PhD Phase 2 trial to determine if low-dose ketamine eases MS fatigue A Phase 2 clinical trial evaluating whether a low dose of ketamine can ease fatigue in people with multiple sclerosis (MS) is enrolling patients at Johns Hopkins University in Baltimore. The study, called INKLING-MS (NCT05378100), is recruiting up to 110 patients, ages 18-65, who have been complaining of fatigue as…
February 15, 2023 News by Margarida Maia, PhD Frequency moving to test agents with remyelination potential Frequency Therapeutics announced that it is shifting its focus to advancing small molecules that aim to restore myelin, the protective cover around nerve fibers that is damaged and lost with multiple sclerosis (MS). This decision follows the failure of an investigative treatment for people with acquired hearing loss to…
February 13, 2023 News by Margarida Maia, PhD Dietitian advice assists MS patients to improve calcium intake: Trial A tailored diet plan from a dietitian may help people with multiple sclerosis (MS) ingest more calcium from foods, which could make their bones stronger and less prone to osteoporosis. That’s according to data from CalciCoach (NCT02664623), a clinical study that compared the amount of dietary calcium consumed…
February 3, 2023 News by Margarida Maia, PhD Crowdfunding Campaign Launched for MS, Other Clinical Programs FibroBiologics has launched an online crowdfunding campaign to support the development of potential therapies in the company’s pipeline and advance its clinical programs in multiple sclerosis (MS) and other diseases. The campaign was begun in collaboration with StartEngine, an equity crowdfunding platform that facilitates investments in startup companies.
February 2, 2023 News by Margarida Maia, PhD Aubagio Significantly Lowers Plasma NfL Levels in TERIKIDS Trial Aubagio (teriflunomide) can significantly reduce plasma neurofilament light chain (pNfL) levels, a biomarker of nerve cell damage, in children and adolescents with relapsing-remitting multiple sclerosis (RRMS). That’s according to a new analysis of data from TERIKIDS (NCT02201108), the Phase 3 trial that supported expanding Aubagio’s indication in…
January 17, 2023 News by Margarida Maia, PhD MS Relapse, Worse Disease More Likely for Smokers: New Study People with relapsing-remitting multiple sclerosis (RRMS) who are receiving oral disease-modifying therapies (DMTs) are still more likely to experience a relapse or any form of disease activity if they are smokers, a study found. Researchers also observed that former smokers had a disease…
December 26, 2022 News by Margarida Maia, PhD MS Comorbidities Lead to Economic Burden for Patients, Study Finds About half of all individuals diagnosed with multiple sclerosis (MS) have at least one other co-occurring medical disorder, and such comorbidities add a significant economic burden for MS patients in managing their condition, according to an Italian study. These added costs result from an increase in the use of…
December 9, 2022 News by Margarida Maia, PhD No Increase in Disease Activity With Longer Lag in Rituximab Treatment People with relapsing-remitting multiple sclerosis (RRMS) who are stable on rituximab treatment may receive the therapy at extended intervals without risking increased MS disease activity, according to a new study. In fact, a longer lag between infusions could potentially reduce the medication’s side effects, researchers say — noting,…
December 8, 2022 News by Margarida Maia, PhD New Patent Filed for EmtinB With Copaxone as Potential MS Therapy NeuroScientific Biopharmaceuticals has filed a patent in Australia to protect the use of its lead candidate EmtinB in combination with Teva’s Copaxone (glatiramer acetate injection) as a potential treatment for multiple sclerosis (MS). The patent application (provisional number 2022903564) is based on data from a lab…